Silicone Elastomer Patents: Top Companies & Filing Trends 2026
- Filings have flattened, not grown. annual filings peaked at 162 in 2020 and have since drifted back toward mid-2010s levels, with the 2026 count still partial.
- Claim density sits in formulation, not structure. C08L polymer compositions and C08K additive chemistry together account for more records than the next four IPC subclasses combined.
- The US is the dominant filing venue. 1,149 records route through the United States, well ahead of the EPO's 843 and more than six times WIPO's PCT filings.
Filing growth compares 2021 (90 records) with 2024 (74) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,213 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families addressing thermal aging resistance, long-term durability, and compression set resistance in silicone elastomers, silicone rubber, and polysiloxane-based materials. The corpus spans 3,213 published records filed between 2015 and mid-2026, drawn from a search string that ties elastomer chemistry directly to reliability performance claims rather than to silicone chemistry in general.
The technology composition points to formulation chemistry as the crowded ground: polymer compositions and additive systems dominate the IPC mix, while layered products, coatings, and implant-related filings form a smaller but persistent secondary cluster. Publication lags filing by roughly 18 months, so the 2026 figure in the trend chart understates actual filing activity for that year.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 3,213-family dataset: how filing volume has moved year over year, and how those filings split across IPC subclasses.
Filings have plateaued since the 2020 peak
Annual filings ran at 135 in 2017, rose to a peak of 162 in 2020, and sat at 129 by the 2022 midpoint before continuing to soften. The 2026 figure of 17 is a partial-year count and should not be read as a collapse — it reflects publication lag, not a stop in filing activity. Taken together, the shape is flat-to-declining rather than growth, which suggests the field is in a consolidation phase where existing players are refining formulations rather than staking new ground.
Formulation chemistry dominates the IPC split
C08L (polymer compositions) leads with 1,111 records, followed by C08K (polymer additives) at 808 — together these two subclasses cover more filings than C08F, C08J, C09D, and C08G combined. B32B (layered products) and A61F (implants and prostheses) round out the mix at lower volumes, marking where silicone durability claims extend into device and laminate applications rather than staying in bulk material chemistry.
Shares are the percentage of the 3,213 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Silicone Elastomer Reliability and Durability with Eureka
This page is one run against one query. Ask Eureka your own question about silicone elastomer reliability and durability and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Millable silicone rubber compound, millable silicone rubber composition, and method for producing millable silicone rubber composition
The filing claims a millable silicone rubber compound built from organopolysiloxane raw rubber, reinforcing silica in a defined surface-area range, a partial hydrolysate of an organoalkoxysilane, and a condensation catalyst selected from a specific set of amine compounds, hexaorganodisilazane, or dilute ammonia water.Filed by Shin-Etsu Chemical, published March 2026 — one of the most recent entries in the dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5480424A | Heart valve replacement using flexible tubes | 1,377 |
| 2 | US6719789B2 | Replacement heart valve | 854 |
| 3 | US20050004668A1 | Annuloplasty rings and methods for repairing cardiac valves | 832 |
| 4 | US6951571B1 | Valve implanting device | 737 |
| 5 | US6126686A | Artificial vascular valves | 692 |
| 6 | US6673109B2 | Replacement atrioventricular heart valve | 632 |
| 7 | US20050203618A1 | Prosthetic cardiac valves and systems and methods for implanting thereof | 564 |
| 8 | US7186265B2 | Prosthetic cardiac valves and systems and methods for implanting thereof | 539 |
| 9 | US20040088045A1 | Replacement heart valve | 481 |
| 10 | US20040148019A1 | Devices and methods for heart valve treatment | 462 |
Citation counts favour older records simply by virtue of being searchable longer; treat them as a signal of influence on the field, not as a marker of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for strategy
Reading the filing and citation data together points to where the field's real activity sits and where it has gone quiet.
Growth has stalled since 2020
The peak of 162 filings in 2020 has not been matched since, and the 2022 midpoint of 129 already showed the decline underway. Even allowing for publication lag on the 2026 figure, the multi-year trend is flat to declining rather than expanding.
Two IPC subclasses carry the bulk of claim density
Polymer compositions and additive chemistry together outweigh the next four subclasses combined, meaning most defensible novelty now sits in specific formulation ratios and additive combinations rather than in broad structural claims.
The US leads filing venue by a clear margin
United States filings outnumber EPO filings by roughly 300 records, and both sit well ahead of WIPO PCT, Japan, India, and Germany. This concentration suggests the US is the primary venue where reliability and durability claims are contested first.
Co-filing is rare and concentrated
Only ten co-assignee pairs appear across the corpus, with the strongest pairing linking a major chemicals producer to a seal and gasket specialist. Most assignees file independently, so joint development programmes are the exception rather than the norm in this space.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to silicone elastomer reliability and durability, with the prior art for and against each one.
Who is filing, and where the room is
Recent-year momentum figures show several established silicone producers with zero or negative year-over-year filing activity, consistent with the broader plateau in the trend data. That pattern doesn't mean these firms have exited the field — it more likely reflects a pause after a prior filing push, combined with the publication lag on the most recent year.
Established filers show flat or declining recent activity
Multiple major assignees recorded zero filings in the latest tracked year, with year-over-year changes at 0% or -100% relative to the prior year. This is consistent with the overall plateau since 2020 rather than a signal that any single firm has stepped back strategically.
A small number of deep partnerships stand out
The strongest co-assignee relationship in the dataset links a major chemicals producer with a seal and bearing specialist, at 20 shared filings — well above the next-strongest pairs at 11 each. These pairings point to specific supply relationships between material formulators and component manufacturers.
Filing strategy centres on the US market first
With 1,149 records routed through the United States compared to 843 through the EPO, most assignees appear to prioritise US protection before pursuing broader international coverage. The relatively low WIPO PCT count of 181 suggests limited early-stage multi-jurisdiction filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Dow Global Technologies LLC | 1 | 0% |
| Zeon Corporation | 0 | -100% |
| FUJIFILM Corporation | 0 | — |
| Mitsui Chemicals, Inc. | 0 | — |
| Daikin Industries, Ltd. | 0 | -100% |
| Shin-Etsu Chemical Co., Ltd. | 0 | — |
| Canon Inc. | 0 | — |
| JSR Corporation | 0 | — |
Where to take this analysis
The dataset points to a mature, US-centred formulation space with narrow but identifiable openings. The next steps depend on whether you are clearing a formulation, tracking a competitor, or scoping new claim territory.
Map a specific formulation against the C08L/C08K cluster
Run a freedom-to-operate style check against the densest IPC subclasses before committing R&D spend to a new additive combination.
Explore in Eureka →Watch the co-assignee pairs for supply-chain signal
The strongest cross-filing relationships in this corpus suggest active formulator-to-component partnerships worth monitoring for licensing moves.
Explore in Eureka →Test the under-claimed branches for a first-mover claim
Sub-areas like recyclable crosslink chemistries and implant-grade compression set testing show thinner filing density relative to the core clusters.
Explore in Eureka →Common questions about this landscape
The dataset's assignee ranking (rendered separately on this page) shows filing activity concentrated among major silicone and specialty chemicals producers, with several of the largest holders showing flat or declining filings in the most recent tracked year. No single company holds a dominant share of the 3,213 families in this corpus; instead, filing is distributed across a handful of established chemicals firms plus a long tail of component and device manufacturers who file around specific applications like seals and implants. Because recent-year momentum for the top holders is at or near zero percent year-over-year, current filing leadership does not necessarily predict who will lead in five years.
Filings peaked at 162 in 2020 and have trended down since, reaching 129 by 2022 and continuing to soften afterward. Part of this apparent decline is a publication-lag artefact — the 2026 figure of 17 is a partial year and will rise as later filings publish — but the multi-year pattern from 2020 through 2022 is a genuine plateau rather than a lag effect alone. This is consistent with a formulation space where core additive and polymer composition claims are already well staked, pushing new activity toward narrower, incremental improvements rather than broad new filings.
Compression set resistance describes how well a silicone elastomer retains its original shape and sealing force after being compressed for an extended period, which is critical for gaskets, seals, and O-rings used in demanding thermal or mechanical environments. In this patent corpus, compression set resistance claims are frequently paired with thermal aging resistance and long-term durability language, and they cluster heavily in the C08L and C08K IPC subclasses covering polymer compositions and additive systems. A practitioner searching for prior art on a new sealing compound should expect dense coverage in these two subclasses specifically, rather than in structural or device-level classes.
The IPC composition data shows filing density concentrated in C08L and C08K, with comparatively thinner coverage in areas like low-temperature cure catalyst systems, reinforcing filler surface treatments, and recyclable crosslink chemistries. These are not unclaimed territories, but they show less filing density relative to the core formulation clusters, which is where a well-drafted first claim has a better chance of standing apart from prior art. Implant-grade compression set testing methodology is another comparatively thin area, given that A61F (implants and prostheses) accounts for a much smaller share of records than the core polymer chemistry subclasses.
The United States leads with 1,149 records, ahead of the European Patent Office at 843, followed by WIPO's PCT route at 181, Japan at 175, India at 154, and Germany at 147. This distribution indicates that most applicants prioritise US protection first and pursue broader international coverage selectively rather than as a default strategy. The relatively low PCT count compared to direct US and EPO filings suggests that many applicants are optimising for their two largest individual markets rather than building broad multi-jurisdiction portfolios early in the filing process.
Research Silicone Elastomer Reliability and Durability in depth with Eureka
Go past this page: query the whole silicone elastomer reliability and durability corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.